# Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids

> **NCT07167251** · — · RECRUITING · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 63 (estimated)

## Conditions studied

- Immune Related Adverse Events
- Immune-Mediated Hepatitis
- Cancer

## Interventions

- **DRUG:** Low-dose corticosteroids for immune-related hepatitis grade 3
- **DRUG:** Low-dose corticosteroids for immune-related hepatitis grade 2

## Key facts

- **NCT ID:** NCT07167251
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-25
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07167251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07167251, "Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07167251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*